4D Molecular Therapeutics (FDMT) News Today $8.83 +0.81 (+10.10%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 15 at 11:17 PM | finanznachrichten.de4D Molecular Therapeutics: Strong Financial Position and Strategic Clinical Advancements Support Buy RatingNovember 15 at 1:46 AM | markets.businessinsider.comAnalyst Expectations For 4D Molecular Therapeutics's FutureNovember 14 at 3:44 PM | benzinga.comPromising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular TherapeuticsNovember 14 at 10:43 AM | markets.businessinsider.com4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 14 at 5:42 AM | finance.yahoo.com4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesNovember 13, 2024 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by Brokerages4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eightNovember 12, 2024 | marketbeat.com4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach OutNovember 1, 2024 | stockhouse.comWe're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash WiselyOctober 31, 2024 | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Drop in Short Interest4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 9,490,000 shares, a decline of 13.2% from the September 30th total of 10,930,000 shares. Based on an average trading volume of 792,200 shares, the short-interest ratio is currently 12.0 days.October 29, 2024 | marketbeat.comNovo Holdings A S Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Novo Holdings A S increased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,500,000 shares of the company's stock after acquiring an additional 100,000 shares duOctober 27, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given an average rating of "Moderate Buy" by the nine research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have giOctober 18, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Short Interest ReportOctober 15, 2024 | benzinga.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Quotes, Forecast and News SummaryOctober 15, 2024 | benzinga.comDimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Dimensional Fund Advisors LP trimmed its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 532,742 shares of the comOctober 7, 2024 | marketbeat.com4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So SureOctober 4, 2024 | seekingalpha.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 10.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 706,000 shares of the company'sOctober 4, 2024 | marketbeat.comMarshall Wace LLP Sells 71,880 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Marshall Wace LLP lowered its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 27.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 185,866 shares of the company's stock aftOctober 3, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. Expected to Post FY2024 Earnings of ($2.68) Per Share (NASDAQ:FDMT)4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Cantor Fitzgerald issued their FY2024 EPS estimates for shares of 4D Molecular Therapeutics in a report issued on Monday, September 23rd. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share oSeptember 25, 2024 | marketbeat.comCantor Fitzgerald Downgrades 4D Molecular Therapeutics (FDMT)September 24, 2024 | msn.comCantor Fitzgerald Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) to NeutralCantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday.September 23, 2024 | marketbeat.com4DMT Announces Presentation at the 2024 North American Cystic Fibrosis ConferenceSeptember 23, 2024 | globenewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Buy" from AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given a consensus rating of "Buy" by the ten brokerages that are covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages thaSeptember 23, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)September 19, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)September 19, 2024 | markets.businessinsider.com4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug CandidateSeptember 19, 2024 | finance.yahoo.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4% 4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 14.4%September 19, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $39.00 Price Target at Chardan CapitalChardan Capital boosted their price objective on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a "buy" rating in a research note on Thursday.September 19, 2024 | marketbeat.com4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development DaySeptember 18, 2024 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading 4.2% Higher 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 4.2%September 18, 2024 | marketbeat.comKaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the FirmSeptember 17, 2024 | tmcnet.comSofinnova Investments Inc. Has $5.69 Million Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Sofinnova Investments Inc. lifted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 36.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,155 shares of the company's stock aSeptember 17, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,413 shares of the comSeptember 15, 2024 | marketbeat.comFDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmSeptember 12, 2024 | businesswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 5.5%4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 5.5%September 10, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of 4D Molecular Therapeutics in a research note on Monday.September 9, 2024 | marketbeat.com4DMT Announces Presentations at Upcoming Retina ConferencesSeptember 5, 2024 | finance.yahoo.com4DMT to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 3, 2024 | globenewswire.comPanagora Asset Management Inc. Has $7.45 Million Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Panagora Asset Management Inc. lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 247.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 354,857 shares of the company's stock after buying aAugust 31, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTAugust 26, 2024 | prnewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lifted by Nisa Investment Advisors LLCNisa Investment Advisors LLC grew its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 5,735.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,698 shares of the company's stock after acquiring aAugust 22, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 3.5%4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 3.5%August 19, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 9,530,000 shares, a decline of 7.8% from the July 15th total of 10,340,000 shares. Based on an average daily volume of 874,700 shares, the days-to-cover ratio is presently 10.9 days.August 19, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTAugust 17, 2024 | prnewswire.comChardan Capital Weighs in on 4D Molecular Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FDMT)4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at Chardan Capital issued their FY2024 earnings estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. Chardan Capital analyst Y. Livshits anticipates thAugust 16, 2024 | marketbeat.com4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTAugust 9, 2024 | prnewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $14.734D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $14.73August 9, 2024 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume IncreaseAugust 7, 2024 | marketbeat.comVanguard Group Inc. Has $74.55 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Vanguard Group Inc. raised its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 25.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,339,943 shares of the company's stAugust 6, 2024 | marketbeat.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military. Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.100.56▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼133▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KNSA News DAWN News SPRY News XNCR News RCUS News NTLA News RCKT News TVTX News AVDL News EVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
